Try Mental Wellness – Lifestyle
Author:
Plus Therapeutics Inc.
Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases
May 8, 2026
Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
May 7, 2026
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
April 28, 2026
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™
April 23, 2026
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 22, 2026
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 21, 2026
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
April 15, 2026
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
April 9, 2026
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
April 8, 2026
Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption
April 7, 2026
1
2
Next Page
→